ClinicaliQ Trial Snapshot
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting • Phase III • Oncology • NCT07492641.
- What is being tested: BGB-43395 (a novel protein degrader) combined with letrozole is being compared against standard CDK4/6 inhibitors plus letrozole as first-line treatment for advanced/metastatic HR+/HER2- breast cancer.
- Patient eligibility overview: Adults with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have not previously received systemic treatment for advanced/metastatic disease are eligible for inclusion.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.
Eligibility Snapshot
- : * Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent. * Participants with histologically confirmed locally advanced or metastatic HR+ HER2- breast cancer. * Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.